Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel)

Jabbour E. Park J. Shaughnessy P. Logan A. Sandhu K. Abedi M. Shah B. Bishop M. DeAngelo D. Lao-Sirieix P. Brugger W. Zhang Y. Roddie C (2025). Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel). Transplantation and Cellular Therapy, 31(2), S216-S217. https://doi.org/10.1016/j.jtct.2025.01.332

Rate and Review Access Paper
Authors
Elias Jabbour, Jae H Park, Paul Shaughnessy, Aaron C Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Yiyun Zhang, Claire Roddie
Journal
Transplantation and Cellular Therapy
First published
2025
Number of citations
1
Type
Journal Article
DOI
10.1016/j.jtct.2025.01.332
Licence
https://www.elsevier.com/tdm/userlicense/1.0/
Licence
https://www.elsevier.com/legal/tdmrep-license

Reviews

No reviews yet for this journal-article.

Be the first to review this journal-article!

Sign in to add a review. Help the research community by sharing your assessment of this journal-article.

Log in Sign up